Tailored induction & maintenance therapy for IBD
“The most effective natural treatment for IBD." - National Survey of leading IBD doctors, IL. 22.
A comprehensive, novel plant-based agent for Crohn’s and Colitis, CurQD® is clinically proven for fast induction, mucosal healing and remission maintenance. Developed by leading GI experts in Sheba Medical Center, one of Newsweek’s best 10 hospitals, we provide online diagnosis and direct delivery of our product to IBD patients after clinical evaluation, eliminating the obstacles associated and time required for conventional medical treatment . With faster, safer and higher remission rates than most pharmaceuticals, the CurQD® Protocol offers significant results within 8-12 weeks and potential for long-term remission with no side effects according to RCTs.*
Protocols Tailored to the Patient
One of the great challenges in treating IBD is that it is not a homogenous disease, but rather a multi-faceted and changeable condition that requires a personalized approach. The CurQD® Protocol is a unique induction therapy that can be tailored to the disease severity and the patient’s changing condition as they progress with treatment. This allows us to address both induction needs and maintenance needs.
In a recent retrospective trial led by our research team in association with leading IBD centers, the strategic use of CurQD® doses resulted in 70.4% of patients with clinical response and 51.1% of patients in complete clinical remission.
This was even observed in patients failing biologics or corticosteroids, demonstrating the prowess of CurQD® as a potential nutraceutical therapy for unresponsive patients. Our top-grade clinical research demonstrates that by personalizing the therapy, we vastly improved patient outcomes.
70.4% of patients showed clinical response and 51.1% of patients showed clinical remission.
At week 8, 50% achieved clinical remission, and 85.7% achieved clinical response.
In a 2023 multi-center randomized controlled trial, UC patients who had all failed at least one line of pharmaceutical UC treatments were given CurQD®.
At week 8, 50% achieved clinical remission, and 85.7% achieved clinical response.
Re-aiming the Target in IBD
Our natural formulas contain molecules that activate a specific immunological pathway initiated by the aryl hydrocarbon receptor (AhR). When activated, this pathway accelerates the reconstitution of intestinal integrity in IBD patients, leading to complete mucosal healing.
Although the AhR pathway was previously overlooked as a potential therapeutic target, it is now the main focus of emerging novel treatments. CurQD® is the first formulation shown in clinical trials to induce remission through the activation of this pathway.
What our patients say
Bosmat (CD)
It exceeded all my expectations. I went back to living fully. Today, a year and 2 months later, I’m still in remission and am grateful every day that I gave your treatment a chance.
Noa (UC)
From the fifth day of taking the QD, I came back to life. The pain stopped, the trips to the bathroom stopped, the bleeding stopped. It truly made the difference between being sick and being healthy. I have no words.
Suzy (CD)
My calprotectin level went from 230 all the way down to 24 in just one month! I am completely blown away by my results! Evinature helped me reach remission and improved my quality of life. I am forever grateful.
Tomer (CD)
I feel a lot better. I no longer suffer from stomach aches and I’m focusing on other things than Crohn’s – focusing on my job, I’m starting to work out. I think it’s really helpful and I recommend it.
Sonya (UC)
I started taking (skeptically) curcumin, QD, and CD capsules – after 1 month I felt better. After 2 months my blood tests were great, and after 6 months, I entered clinical and endoscopic remission.
Almog (UC)
I was shocked. My symptoms got dramatically better. I was shocked that a plant had a much stronger effect than very high dosages of steroids and very powerful medications.
Hadar (CD)
After a month and a week, I started to feel a very significant change! In the tests I did, the indices came out almost completely normal! It’s a real miracle!
Shahar (CD)
To my absolute surprise, it worked. I think within 48 hours there was a real change in the flare. It took about 14 days to go completely into remission.
Batel (UC)
After a few days, there was a significant improvement in my condition, I achieved remission. In the last calprotectin test, I got 20!
Tal (UC)
It was like magic. I mean, after two weeks I was in the best condition I’d had in 16 years. I just couldn’t beleive it. After 6 months, I was diagnosed with full remission.
Approved by Leading Gastroenterologists
“My experience with this combination is very good. We’ve had some patients who were able to avoid advancing them to biologics, and others we could give this combination to instead of steroids. ”
~ Dr. Dror Shoval MD, Senior Pediatric Gastroenterologist
“I admit I was skeptical about these treatments. But with time I realized patients were reporting a significant benefit and I was surprised to see that they were improving – not just subjectively but objectively.”
~ Henit Yanai MD, Senior Gastroenterologist
Developed in Sheba Medical Center
The CurQD® Protocol was developed by Professor Shomron Ben-Horin (MD) and Nir Salomon (C.Ac, C.Hb) in the leading IBD research center of Sheba Medical Center, one of Newsweek’s best 10 hospitals in the world.
Ben-Horin and Salomon have spearheaded the research and development of nutraceuticals for IBD over the last decade. Their breakthrough CurQD® therapy is currently the most effective natural strategy for IBD and has been successfully integrated into the clinical practice of leading GI medical centers in Israel.
The team behind CurQD®
Nir Salomon, C.Ac, C.H.b
Prof. Ben-Horin MD
Chief of the Gastroenterology Department at Sheba Medical Center Tel-Aviv University, named by Newsweek magazine as one of the top 10 medical centers in the world for three consecutive years. Shomron Ben-Horin M.D. was previously a member of the Scientific Committee of the European Crohn’s and Colitis Organization (ECCO) and Chair of the Israeli IBD Society. He is currently a member of the prestigious International Organization of IBD (IOIBD).
*In our latest RCT, no serious adverse events were reported and all side effects were comparable to placebo. In our retrospective trial, the mild, transient, reversible elevation of liver enzymes was reported in 5% of patients.
For more information on adding CurQD® to your treatment, see our Guidelines for Healthcare Professionals.